149 related articles for article (PubMed ID: 27817195)
1. Mechanisms underlying lung resistance-related protein (LRP)-mediated doxorubicin resistance of non-small cell lung cancer cells.
Chen YL; Yang TY; Wu CL; Chen KC; Hsu SL; Hsueh CM
Chin J Physiol; 2016 Dec; 59(6):331-347. PubMed ID: 27817195
[TBL] [Abstract][Full Text] [Related]
2. The formation of vault-tubes: a dynamic interaction between vaults and vault PARP.
van Zon A; Mossink MH; Schoester M; Houtsmuller AB; Scheffer GL; Scheper RJ; Sonneveld P; Wiemer EA
J Cell Sci; 2003 Nov; 116(Pt 21):4391-400. PubMed ID: 13130096
[TBL] [Abstract][Full Text] [Related]
3. Cryoelectron microscopy imaging of recombinant and tissue derived vaults: localization of the MVP N termini and VPARP.
Mikyas Y; Makabi M; Raval-Fernandes S; Harrington L; Kickhoefer VA; Rome LH; Stewart PL
J Mol Biol; 2004 Nov; 344(1):91-105. PubMed ID: 15504404
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
5. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer.
Scheffer GL; Schroeijers AB; Izquierdo MA; Wiemer EA; Scheper RJ
Curr Opin Oncol; 2000 Nov; 12(6):550-6. PubMed ID: 11085454
[TBL] [Abstract][Full Text] [Related]
6. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs.
Berger W; Elbling L; Micksche M
Int J Cancer; 2000 Oct; 88(2):293-300. PubMed ID: 11004683
[TBL] [Abstract][Full Text] [Related]
7. Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer.
Szaflarski W; Sujka-Kordowska P; Pula B; Jaszczyńska-Nowinka K; Andrzejewska M; Zawierucha P; Dziegiel P; Nowicki M; Ivanov P; Zabel M
Int J Oncol; 2013 Aug; 43(2):513-20. PubMed ID: 23739867
[TBL] [Abstract][Full Text] [Related]
8. vPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Anticancer Res; 2017 Jun; 37(6):3015-3023. PubMed ID: 28551640
[TBL] [Abstract][Full Text] [Related]
9. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells.
Meschini S; Marra M; Calcabrini A; Monti E; Gariboldi M; Dolfini E; Arancia G
Toxicol In Vitro; 2002 Aug; 16(4):389-98. PubMed ID: 12110277
[TBL] [Abstract][Full Text] [Related]
10. Analysis of MVP and VPARP promoters indicates a role for chromatin remodeling in the regulation of MVP.
Emre N; Raval-Fernandes S; Kickhoefer VA; Rome LH
Biochim Biophys Acta; 2004 Apr; 1678(1):33-46. PubMed ID: 15093136
[TBL] [Abstract][Full Text] [Related]
11. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo.
Liu Y; Snow BE; Kickhoefer VA; Erdmann N; Zhou W; Wakeham A; Gomez M; Rome LH; Harrington L
Mol Cell Biol; 2004 Jun; 24(12):5314-23. PubMed ID: 15169895
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis.
Raval-Fernandes S; Kickhoefer VA; Kitchen C; Rome LH
Cancer Res; 2005 Oct; 65(19):8846-52. PubMed ID: 16204055
[TBL] [Abstract][Full Text] [Related]
13. Characterization of MVP and VPARP assembly into vault ribonucleoprotein complexes.
Zheng CL; Sumizawa T; Che XF; Tsuyama S; Furukawa T; Haraguchi M; Gao H; Gotanda T; Jueng HC; Murata F; Akiyama S
Biochem Biophys Res Commun; 2005 Jan; 326(1):100-7. PubMed ID: 15567158
[TBL] [Abstract][Full Text] [Related]
14. Cellular functions of vaults and their involvement in multidrug resistance.
Steiner E; Holzmann K; Elbling L; Micksche M; Berger W
Curr Drug Targets; 2006 Aug; 7(8):923-34. PubMed ID: 16918321
[TBL] [Abstract][Full Text] [Related]
15. [The structure of cellular vaults, their role in the normal cell and in the multidrug resistance of cancer].
Szaflarski W; Nowicki M; Zabel M
Postepy Biochem; 2011; 57(3):266-73. PubMed ID: 22235652
[TBL] [Abstract][Full Text] [Related]
16. Structural domains of vault proteins: a role for the coiled coil domain in vault assembly.
van Zon A; Mossink MH; Schoester M; Scheffer GL; Scheper RJ; Sonneveld P; Wiemer EA
Biochem Biophys Res Commun; 2002 Mar; 291(3):535-41. PubMed ID: 11855821
[TBL] [Abstract][Full Text] [Related]
17. Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression.
van Zon A; Mossink MH; Schoester M; Scheper RJ; Sonneveld P; Wiemer EA
Cancer Res; 2004 Jul; 64(14):4887-92. PubMed ID: 15256459
[TBL] [Abstract][Full Text] [Related]
18. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.
Kitazono M; Sumizawa T; Takebayashi Y; Chen ZS; Furukawa T; Nagayama S; Tani A; Takao S; Aikou T; Akiyama S
J Natl Cancer Inst; 1999 Oct; 91(19):1647-53. PubMed ID: 10511592
[TBL] [Abstract][Full Text] [Related]
20. Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line.
Huffman KE; Corey DR
Biochemistry; 2005 Feb; 44(7):2253-61. PubMed ID: 15709737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
